REVIEW
New targets for the therapy of Pulmonary Arterial Hypertension (PAH) Nebulized anti-miRs against miR-138 and miR-25 completely regress monocrotaline-induced PAH
 
More details
Hide details
1
Academic Department of Pneumonology, Hospital for Diseases of the Chest, “Sotiria”, Medical School, University of Athens, Messogion Avenue 152, Athens, Greece
 
2
Division of Immunology, Biomedical Sciences Research Center “Alexander Fleming”, Vari, Athens, Greece
 
 
Publication date: 2021-06-16
 
 
Corresponding author
Argyris Tzouvelekis   

Biomedical Sciences Research Center “Alexander Fleming”, Division of Immunology, Vari 16672, Athens, Greece
 
 
Pneumon 2016;29(3):236-237
 
 
REFERENCES (7)
1.
Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010;121:2045-66.
 
2.
Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USAbased registry for pulmonary arterial hypertension: 1982-2006. ERJ 2007;30:1103-10.
 
3.
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012;142:448-56.
 
4.
Hong Z, Chen KH, Dasgupta A, et al. miR-138 and miR-25 Downregulate MCU, Causing Pulmonary Arterial Hypertension’s Cancer Phenotype. American Journal of Respiratory and Critical Care Medicine 2016.
 
5.
Santulli G, Xie W. Mitochondrial calcium overload is a key determinant in heart failure. 2015;112:11389-94.
 
6.
Pan L, Huang BJ, Ma XE, et al. MiR-25 protects cardiomyocytes against oxidative damage by targeting the mitochondrial calcium uniporter. International Journal of Molecular Sciences 2015;16:5420-33.
 
7.
Yan H, Zhang D, Hao S, Li K, Hang CH. Role of Mitochondrial Calcium Uniporter in Early Brain Injury After Experimental Subarachnoid Hemorrhage. Molecular Neurobiology 2015;52:1637-47.
 
eISSN:1791-4914
ISSN:1105-848X
Journals System - logo
Scroll to top